-
In this issue: Aspirin dose and cardioprotection; uncovering modafinil's abuse potential; proton-pump inhibitors and clopidogrel; FDA actions.
-
Fortunately, at a time when there is an emphasis on evidence-based reasons for medical decisions, more reviews are appearing in the literature looking at various common interventions and the evidence available to support these practices.
-
The primary objective of the PLCO study is to evaluate the impact of annual screening with transvaginal ultrasound (TVUS) and CA125 on ovarian cancer mortality. The study is prospectively following a cohort of more than 34,000 largely postmenopausal women with intact ovaries with an algorithm where either an abnormal CA125 (e" 35 units/mL) or an abnormality on TVUS is considered a positive screen.
-
To incorporate evidence-based guidelines into both practice and research, the Research and Development Committee of the International Urogynecological Association embarked on a lengthy process, which included a literature review, creation of recommendations, incorporation of expert consultant opinion, writing a white paper for association members, final revision, and then publication in its journal.
-
-
It has been very difficult to study the effects of alcohol on the fetus and on pregnancy, in general, because one depends so heavily on a patient's candor regarding true alcohol consumption and the effect of confounding variables, such as smoking.
-
The standard primary surgical intervention for early-stage uterine cancer is hysterectomy, usually with removal of the adnexa.
-
The livial intervention following breast cancer: Efficacy, Recurrence, And Tolerability Endpoints (LIBERATE) trial was a multinational, placebo-controlled, randomized study of women with vasomotor symptoms who had had breast cancer surgically treated within the previous 5 years.
-
In this issue: Individualization of therapy with pharmacogenetics; the rate vs rhythm debate; the FDA's Risk Evaluation and Mitigation Strategy; FDA actions.
-
Forty-one women with symptomatic, histologically proven endometriosis (Stages 1-4) were randomized to receive either a contraceptive implant (Implanon®) or depot medroxyprogesterone acetate (DMPA).